The COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday reviewed the data and accepted it. Their recommendations have been sent to the DCGI now, a source said.
Covaxin manufacturer Bharat Biotech said its service provider, IQVIA, has started final statistical analysis.
New Delhi: Bharat Biotech has said that it will be advisable to participate in the Phase 3 efficacy trial for its indigenous Covaxin and get vaccinated to ensure protection against Covid-19 as it may take months for people above 50 years to get the vaccine. In frequently asked questions (FAQ) on its vaccine trials, Bharat […]